We expect 2020 to be a major turning point for Telix Pharmaceuticals. The regulatory submissions for illumet will determine whether the company will start commercial operations in 2021. The clinical groundwork for TLX-250-CDx is being laid in the ongoing pivotal Phase III ZIRCON study, which recently restarted in Europe and is expected to be fully enrolled by the end of 2020. Finally, the company has guided towards starting new clinical studies for TLX591 and TLX250 in late 2020, contingent o
03 Jul 2020
Telix Pharmaceuticals - Major developments coming up
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Telix Pharmaceuticals - Major developments coming up
Telix Pharmaceuticals Ltd. (TLX:ASX) | 0 0 0.0%
- Published:
03 Jul 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
19
We expect 2020 to be a major turning point for Telix Pharmaceuticals. The regulatory submissions for illumet will determine whether the company will start commercial operations in 2021. The clinical groundwork for TLX-250-CDx is being laid in the ongoing pivotal Phase III ZIRCON study, which recently restarted in Europe and is expected to be fully enrolled by the end of 2020. Finally, the company has guided towards starting new clinical studies for TLX591 and TLX250 in late 2020, contingent o